Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp.
Your view on PHIO
Overview
What the company does, where it operates, and who runs it.
About Phio Pharmaceuticals Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Robert J. Bitterman
- Headquarters
- 257 Simarano Drive, Marlborough, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Robert J. Bitterman
- Headquarters
- 257 Simarano Drive, Marlborough, MA, US
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system.
The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT.
It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Phio Pharmaceuticals Corp., and the rating behind it. PHIO last traded at $1.03; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Phio Pharmaceuticals Corp.. Starting points for Phio Pharmaceuticals Corp.: EPS -$1.11, beta 0.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Phio Pharmaceuticals Corp.. Phio Pharmaceuticals Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Phio Pharmaceuticals Corp.. Trailing twelve-month EPS for Phio Pharmaceuticals Corp. stands at -$1.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Phio Pharmaceuticals Corp.. Phio Pharmaceuticals Corp. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Phio Pharmaceuticals Corp. valued side by side against its closest peers. Phio Pharmaceuticals Corp. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Phio Pharmaceuticals Corp., and how their positions are changing. At a $12.0M market value, institutional positions materially move Phio Pharmaceuticals Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Phio Pharmaceuticals Corp. executives and directors. Shares of Phio Pharmaceuticals Corp. have traded between $0.97 and $9.79 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Phio Pharmaceuticals Corp.. Phio Pharmaceuticals Corp. is a $12.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Phio Pharmaceuticals Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Phio Pharmaceuticals Corp.. Coverage tracks Phio Pharmaceuticals Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.